What is gf20

I give consent to London Pain Clinic processing data about myself and my medication condition. To review our privacy policy please click here. By checking this box you agree to your contact details being used so we can contact you about your enquiry. Synvisc Hylan GF20 Introduction Synvisc Hylan GF20 is a form of viscosupplementation treatment designed for relief from knee pain associated with osteoarthritis. Usage and Application Synvisc Hylan GF20 is generally advised for patients who: Are not experiencing satisfactory pain relief from the present treatment Cannot take aspirin or other anti-inflammatory drugs such as ibuprofen Are already taking multiple oral medications Are not appropriate candidates for knee surgery Have not responded well to bracing and use of canes or crutches Have shown inadequate response to measures such as weight loss and physical therapy Recently, it also received European approval to expand its usage to treat the pain associated to osteoarthritis of ankle and the shoulder, in addition to its established use in knee and hip OA.

Research Findings A series of research reports indicate towards favourable results associated with the use of Synvisc Hylan GF20 for treating pain of knee osteoarthritis. Working Principle When a patient suffers from osteoarthritis, the synovial fluid becomes thinner than normal, making it less effective as a lubricant and a shock absorber. For best results, it is always advisable to take all the three injections. Get in touch with us.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides.

The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist. This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use and Privacy Policy.

Learn how we develop our content. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. What is the most important information I should know about hylan G-F 20? What is hylan G-F 20? Hylan G-F 20 is used to treat knee pain caused by osteoarthritis. Hylan G-F 20 may also be used for purposes not listed in this medication guide.

What should I discuss with my health care provider before receiving hylan G-F 20? Hylan G-F 20 is generally not used in anyone younger than 21 years old. Allergic reactions, some which can be potentially severe, were observed during the use of Synvisc-One. If any of the above side effects or symptoms appear after you are given Synvisc-One, or if you have any other problems, you should call your doctor.

As shown in a medical study of patients with osteoarthritis OA of the knee, where approximately half received either a single injection of Synvisc-One or an injection of the same volume of salt water a "Saline Control" injection , the major benefits of Synvisc-One are pain relief and improvement in other symptoms related to OA of the knee. It is recommended you avoid strenuous activities for example, high-impact sports such as tennis or jogging or prolonged weight-bearing activities for approximately 48 hours following the injection.

You should consult your doctor regarding the appropriate time to resume such activities. If any of the side effects or symptoms described above appear after you are given Synvisc-One, or if you have any other problems, you should call your doctor. A study was conducted in 6 countries outside the United States with 21 physicians. The patients in the study had mild to moderate knee OA, moderate to severe pain, and did not have sufficient relief of their pain and symptoms with medications taken by mouth.

Neither the patients nor the doctors evaluating them knew which treatment they received. Any fluid that was present in the patient's knee was removed before the injection. The patients were seen by their doctor at standard times over 6 months. Information was collected about how much pain they were experiencing doing various types of activities, how much they were limited in their daily activities by their OA, and on their overall condition. Their doctor also provided an overall rating of their OA.

The main measure of the study was how much pain the subjects had doing five common types of activities over the 6 months duration of the study.

Daily activity limitations and overall evaluations were also compared between the group of patients receiving Synvisc-One injection and the group receiving salt water injection. The study showed that patients receiving Synvisc-One had significantly less pain over 6 months, and felt significantly better than the patients who received the salt water injections. The difference in pain score reduction from baseline to 6 months between the Synvisc-One and salt water control injection was 0.

The following are the most common adverse events that occurred during the clinical trial of Synvisc-One:. Severe adverse events were not observed in the Synvisc-One trial. Joint infections did not occur in the injected knee in the Synvisc-One clinical trial. The most commonly occurring adverse events outside of the injected knee were headache, back pain, sore throat and the flu.

One patient had a single episode of feeling faint. User Assistance. Note: Patients are counted once for each unique AE regardless of device relatedness, and may have had more than one unique AE. No significant difference was reached for other group and subgroup analyses. Conclusion: According to the current results, limited evidence showed a superior effect favoring hylan G-F 20 over LMWHA in the period from 2 to 3 months post-injection for pain-related outcomes.

There was no evidence of increased risk of treatment-related adverse events for hylan G-F 20 injections.